Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • rare skin diseases

    - PMLiVE

    Almirall and Absci expand AI dermatological drug discovery partnership

    The alliance has already led to the delivery of functional antibody leads against a difficult-to-drug target

    - PMLiVE

    Almirall hosts Skin Academy to advance skin science and dermatology treatments

    The conference will cover actinic keratosis, psoriasis, atopic dermatitis and other skin diseases

    - PMLiVE

    Eli Lilly/Almirall share positive long-term results for Ebglyss in atopic dermatitis

    The inflammatory skin condition occurs in approximately 7.3% of adults in the US

    - PMLiVE

    Almirall announces NICE recommendation for Ebglyss in atopic dermatitis

    The inflammatory skin condition affects about 5.2 million adults and 2.5 million children in the UK

    - PMLiVE

    Almirall’s Ilumetri shown to improve and maintain well-being in plaque psoriasis patients

    Nearly 77% of psoriasis patients report that the condition negatively affects their well-being

    - PMLiVE

    Almirall’s Klisyri receives expanded FDA approval to treat actinic keratosis

    The precancerous condition is responsible for an estimated 60% of all squamous cell carcinoma cases

    - PMLiVE

    Almirall survey reveals limited knowledge of most common precancerous skin condition

    An estimated 60% of squamous cell carcinoma cases, the second most common skin cancer, develop from AK lesions

    - PMLiVE

    Almirall gains rights to Eloxx’s rare dermatological disease asset in deal worth over $470m

    ZKN-013 is designed to overcome nonsense mutations in rare skin diseases such as junctional epidermolysis bullosa

    - PMLiVE

    Almirall gains rights to Novo Nordisk’s IL-21 blocker for dermatological diseases

    NN-8828 has been developed up to phase 2 in non-dermatological indications

    - PMLiVE

    Almirall and CRG partner to advance therapeutic approaches for atopic dermatitis

    The inflammatory skin disease currently affects an estimated 4.4% of adults in the EU

    - PMLiVE

    Almirall and Microsoft partner to accelerate digital transformation in medical dermatology

    The alliance is aimed at advancing the research of solutions for dermatological diseases

    - PMLiVE

    Almirall and etherna partner to develop mRNA-based therapies for severe skin diseases

    Dermatological diseases are estimated to affect 1.8 billion people worldwide

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links